Last edition
News about "ARO-MAPT Phase 1/2a study"
Arrowhead Reports Interim Phase 1/2a Data for ARO-MAPT
Arrowhead Pharmaceuticals has reported interim phase 1/2a ARO-MAPT data showing deep, durable tau reductions in healthy volunteers.
ARO-MAPT Phase 1/2a Study | 15/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members